~~<i id='D8966D6CF7'><strike id='D8966D6CF7'><tt id='D8966D6CF7'><pre id='D8966D6CF7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：comprehensive 2025-09-07 06:42:37 - browse：228

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Why some people catch Covid but never get sick

Wikipedia

hotspot

knowledge

Wikipedia

focus

0:29AnemergencyslidefellfromaplaneandlandedoutsideofahomenearO'HareAirportinChicago,July17,2023.Laur

WSS

Creating egg and sperm cells from stem cells raises ethical issues

Physicians and social media: If you see something, say something?

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

U.K. researchers warn about biases in medical devices, algorithms

Stop the failed accountable care organization experiment

leisure time

leisure time

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Dobbs anniversary: the lost opportunity of abortion as health care

Health AI adoption puts security, privacy startups on investors' radar

Cancer drug shortages should be causing more outrage

Resistance to cancer drugs: A new genetic explanation

Novavax promises a turnaround & Lilly roils the obesity market

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

hotspot

Neuroscience’s long legacy of racism

UnitedHealth increases loan offers after Change Healthcare outage

Plastic surgeons increase patient psychiatric screenings

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Trump got a 'target letter.' What is one and what does it mean?

knowledge

Wikipedia

focus

focus